Radiopharm clears FDA meeting hurdle as RAD101 moves towards Phase 3

FDA meeting moves RAD101 towards pivotal testing

Radiopharm Theranostics Limited (ASX:RAD, Nasdaq: RADX) has cleared an important regulatory checkpoint for RAD101, saying its End-of-Phase 2 meeting with the U.S. Food and Drug Administration produced a constructive framework for the imaging agent’s pivotal development in brain metastases.

The company is now advancing clinical and operational planning for Phase 3, although the most consequential detail is still to come. Radiopharm expects the FDA’s official meeting minutes within approximately 30 days, and those minutes will provide the formal record of the Agency’s feedback on the proposed pivotal programme.

Phase 2b data provide the programme’s foundation

RAD101 is an investigational fluorine-18-labelled small-molecule agent designed to target fatty acid synthase, or FASN, a protein overexpressed in cerebral metastases from solid tumours. In its previously reported Phase 2b trial, RAD101 showed 93% concordance with MRI across all evaluable lesions, meeting the study’s primary endpoint.

That result gives Radiopharm a defined clinical signal to take into its pivotal planning, but it does not itself establish regulatory approval. RAD101 remains an investigational product, and the final Phase 3 design, registration requirements and timing are not disclosed in the announcement.

Manufacturing support and partnership options

Radiopharm said its partnership with Siemens Healthineers will support the manufacture and distribution of 18F-labelled RAD101 doses for the anticipated U.S. Phase 3 registrational trial. The company has also received FDA Fast Track Designation for the agent, including its intended use in distinguishing recurrent disease from treatment effects in brain metastases arising from different solid tumours.

Chief executive Riccardo Canevari said Radiopharm is evaluating potential strategic partners as it prepares for pivotal development. That introduces a second potential avenue for the programme, though the company has not disclosed the structure, timing or commercial terms of any partnership discussions.

The next regulatory document matters most

The FDA meeting itself is a positive development for RAD101, but the company’s description remains preliminary until the written minutes arrive. Any changes to the proposed trial design or additional regulatory requirements could affect how quickly the programme advances and what resources it requires.